Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones September 26, 2022 CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US - Read More September 10, 2022 CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination - Read More September 5, 2022 CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress - Read More Load MoreLoadingMeet us at the following conferences & events ESMO 2022 September 9-13, 2022 Paris, France Read More 22nd Annual Biotech forum September 21-22, 2022 Basel, Switzerland Read More BIO-Europe 2022 October 24-26 Leipzig, Germany Read More SITC 2022 November 8-12, 2022 Boston, MA, USA Read More
